View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S

Despite a better risk assessment and improving to Neutral, BAUSCH HEAL...

BAUSCH HEALTH (US), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date April 5, 2022, the closing price was USD 23.23 and its ...

Despite a better risk assessment and improving to Neutral, BAUSCH HEAL...

BAUSCH HEALTH (CA), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date March 22, 2022, the closing price was CAD 30.24 and its...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 09 14

Current market expectations for IIVI don't comprehend the company's macro tailwinds. The company supplies the technology that allows big macro trends around 5G, the Internet of Things, and autonomous vehicles to bloom. Its tailwinds from these markets continue to take off, and in the case of autonomous vehicles, it is essential to any success at all. As booming demand accelerates in these end markets, the company is likely to see strong fundamental momentum the market isn't pricing in, both...

Valens Research
  • Valens Research

BHC - Embedded Expectations Analysis - 2021 09 08

Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.5x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about their debt issues, Solta and B&L spinoffs, and their revenue guidance, market expectations are overly bearish, and longer-term equity outperformance is warranted. Specifically, management may lack confidence in their ability to continue to pay d...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 06 08

Even after the company's impressive rally, current market expectations for PENN are still too pessimistic. While markets expect UAFRS-based ROA (Uniform ROA or ROA') to improve to levels not seen since 2010-2012, the company has significant further upside in returns, and therefore valuations. The market is not fully recognizing how the company's sports betting strategy, centered around its Barstool investment, can help significantly turbocharge returns and also give a material lift to the exis...

Valens Research
  • Valens Research

BHC - Embedded Expectations Analysis - 2021 06 04

Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 13.0x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, revenue and margin growth, and the potential of their treatment trials, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may lack confidence in their a...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 03 23

LPLA has significantly transformed their business returns, but the market is expecting the company to give operational improvements back. The market is expecting UAFRS-based (Uniform) ROA (ROA') to fade from 30% in 2019 to 18% in 2024, with Uniform asset growth of around 7.5% a year going forward. The market does not think the company's improvement in Uniform ROA from 15%-20% levels historically to towards 30%+ is sustainable, and is expecting the company to see its operating leverage rever...

Valens Research
  • Valens Research

BHC - Embedded Expectations Analysis - 2021 03 19

Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.3x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, their R&D pipeline, and new product launches, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may have concerns about the impact of potential divestit...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2020 12 29

Current market expectations for CVS are excessively pessimistic. Markets expect UAFRS-based (Uniform) ROA (ROA') to roll over to prior lows from 2010-2011. However, the company's fundamental strategy is likely to lead to continued ROA' expansion. CVS has been evolving into a full-service healthcare firm since their acquisition of Caremark in 2007, which led to initial ROA' expansion to 15%-17% levels. This was followed by continued investment in healthcare solutions and monetizing their data o...

Valens Research
  • Valens Research

BHC - Embedded Expectations Analysis - 2020 12 22

Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 9.2x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, operational cash flow guidance, and inventory management, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may lack confidence in their ability to meet t...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch